Michael Barbella, Managing Editor02.27.23
South Korea has become a preferred destination in recent years for medical tourism. Transforming into such a hub has benefitted the country's ophthalmic devices market, which accounted for 8% of the Asia-Pacific (APAC) sector in 2022, according to GlobalData.
Augmented by continuous innovation, South Korea uses artificial intelligence (AI) to diagnose and treat ophthalmic diseases. As a result, the value of the ophthalmic devices market in South Korea is expected to grow about 2% annually to reach $156 million in 2030, forecasts GlobalData.
“Ocular diseases such as diabetic retinopathy, age-related macular degeneration, glaucoma, and cataract are diagnosed only after irreversible damage to vision has already occurred," said Ayshi Ganguly, a Medical Devices analyst at GlobalData. "Companies are incorporating AI in ophthalmic devices to automate the diagnosis of ocular diseases before the structural and functional loss of an eye. This approach will significantly reduce vision loss and improve the accuracy of predicting the risk of patient developing eye-threatening diseases in the future.”
In light of this, South Korea-based Edenlux has announced a report on how eye health management can be facilitated using AI for the users of its flagship product Otus Plus. The incorporation of AI is enabling users to test their eye health using a spectacle-like device at home. In addition to this, one can perform eye exercises with their own custom lenses and receive test reports through an app that is part of the offering.
“Domestic and multinational ophthalmic companies are anticipated to further invest in AI and software as medical devices (SaMD) based ophthalmological diagnostic devices to expand their business. This will further help them increase their market share and likely enable a paradigm shift in the treatment of ophthalmic diseases in the coming years,” Ganguly stated.
Augmented by continuous innovation, South Korea uses artificial intelligence (AI) to diagnose and treat ophthalmic diseases. As a result, the value of the ophthalmic devices market in South Korea is expected to grow about 2% annually to reach $156 million in 2030, forecasts GlobalData.
“Ocular diseases such as diabetic retinopathy, age-related macular degeneration, glaucoma, and cataract are diagnosed only after irreversible damage to vision has already occurred," said Ayshi Ganguly, a Medical Devices analyst at GlobalData. "Companies are incorporating AI in ophthalmic devices to automate the diagnosis of ocular diseases before the structural and functional loss of an eye. This approach will significantly reduce vision loss and improve the accuracy of predicting the risk of patient developing eye-threatening diseases in the future.”
In light of this, South Korea-based Edenlux has announced a report on how eye health management can be facilitated using AI for the users of its flagship product Otus Plus. The incorporation of AI is enabling users to test their eye health using a spectacle-like device at home. In addition to this, one can perform eye exercises with their own custom lenses and receive test reports through an app that is part of the offering.
“Domestic and multinational ophthalmic companies are anticipated to further invest in AI and software as medical devices (SaMD) based ophthalmological diagnostic devices to expand their business. This will further help them increase their market share and likely enable a paradigm shift in the treatment of ophthalmic diseases in the coming years,” Ganguly stated.